![](/images/graphics-bg.png)
PPP1R12A Copy Number Is Associated with Clinical Outcomes of Stage III CRC Receiving Oxaliplatin-Based Chemotherapy
Joint Authors
Zhang, Chenbo
Li, Ajian
Li, Huaguang
Peng, Kangsheng
Wei, Qing
Lin, Moubin
Liu, Zhanju
Yin, Lu
Li, Jianwen
Source
Issue
Vol. 2015, Issue 2015 (31 Dec. 2015), pp.1-7, 7 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2015-05-31
Country of Publication
Egypt
No. of Pages
7
Main Subjects
Abstract EN
Aim.
To investigate the correlation between PPP1R12A gene copy number and clinical outcomes of oxaliplatin-based regimen in stage III colorectal cancer (CRC).
Methods.
A total of 139 paraffin-embedded tissue samples of stage III CRC patients who received oxaliplatin-based treatment after radical surgery were recruited.
Genomic DNA was extracted and purified from paraffin-embedded sections.
Quantitative PCR methods were used to detect the relative copy number (RCN) of PPP1R12A.
Results.
Statistical analysis demonstrated that low PPP1R12A RCN was associated with poor RFS (HR=2.186, 95% CI: 1.293–3.696; P=0.003) and OS (HR=2.782, 95% CI: 1.531–5.052; P<0.001).
Additionally, when patients were stratified according to subgroups of stage III and tumor location, poor RFS and OS were also observed in the low PPP1R12A RCN group with significance (RFS: IIIB HR=2.870, P<0.001; colon HR=1.910, P=0.037; OS: IIIB HR=3.527, P<0.001; IIIC HR=2.662, P=0.049; rectum HR=4.229, P=0.002).
Conclusion.
Our findings suggest the copy number of PPP1R12A can independently predict recurrence and overall survival of stage III colorectal cancer patients receiving oxaliplatin-based chemotherapy.
American Psychological Association (APA)
Zhang, Chenbo& Li, Ajian& Li, Huaguang& Peng, Kangsheng& Wei, Qing& Lin, Moubin…[et al.]. 2015. PPP1R12A Copy Number Is Associated with Clinical Outcomes of Stage III CRC Receiving Oxaliplatin-Based Chemotherapy. Mediators of Inflammation،Vol. 2015, no. 2015, pp.1-7.
https://search.emarefa.net/detail/BIM-1072316
Modern Language Association (MLA)
Zhang, Chenbo…[et al.]. PPP1R12A Copy Number Is Associated with Clinical Outcomes of Stage III CRC Receiving Oxaliplatin-Based Chemotherapy. Mediators of Inflammation No. 2015 (2015), pp.1-7.
https://search.emarefa.net/detail/BIM-1072316
American Medical Association (AMA)
Zhang, Chenbo& Li, Ajian& Li, Huaguang& Peng, Kangsheng& Wei, Qing& Lin, Moubin…[et al.]. PPP1R12A Copy Number Is Associated with Clinical Outcomes of Stage III CRC Receiving Oxaliplatin-Based Chemotherapy. Mediators of Inflammation. 2015. Vol. 2015, no. 2015, pp.1-7.
https://search.emarefa.net/detail/BIM-1072316
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1072316